Roivant Sciences Ltd stock hit an all-time high of $30.35. Currently trading at $30.64 with a market cap of $20.2 billion, the stock has surged 156% over the past year.
According to Bond.az analysis, the stock appears overvalued at current levels. The biotech firm, known for innovative drug development, has captured investor interest.
In recent news, Roivant reported Q4 2026 earnings per share of $0.28, beating expectations of -$0.29. Revenue came at $2.52 million, below the expected $3.76 million, marking a mixed result.
